Although the first description of salivary duct carcinoma (SDC) dates back to 1968,¹ the tumor was not officially recognized as a distinct entity by the World Health Organization until 1991.² Salivary duct carcinoma is characterized by peculiar clinical and pathologic features. Most patients are older than 40 years, with an approximate male to female ratio of 3:1. Ninety-five percent of lesions arise in the major salivary glands,³ especially the parotid,⁴ and only occasionally are the minor glands involved. The tumor can develop de novo or in a preexisting pleomorphic adenoma or polymorphous low-grade adenocarcinoma. Salivary duct carcinoma has an aggressive clinical behavior with a tendency for early facial nerve infiltration, extraparotid growth, and regional and distant spreading.⁴ The survival rate is poor, with more than 60% of patients dying of the tumor within 3 years despite aggressive treatment, generally consisting of surgical resection and radiotherapy.^4-6 The most peculiar histologic feature of this neoplasm is its resemblance to ductal carcinoma of the breast, with both intraductal (or in situ) and invasive components.